What is the typical dosing regimen for Cipro (ciprofloxacin) in treating bacterial infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ciprofloxacin Dosing Regimens for Bacterial Infections

The typical dosing regimen for ciprofloxacin varies by infection type, with oral dosing generally ranging from 250-750 mg twice daily and intravenous dosing of 400 mg every 8-12 hours, with adjustments needed for renal impairment. 1

Adult Oral Dosing

Infection Type Dosage Duration
Uncomplicated UTI 250-500 mg twice daily 3 days
Complicated UTI/Pyelonephritis 500 mg twice daily 7-14 days
Respiratory infections 500-750 mg twice daily 7-14 days
Skin/soft tissue infections 500-750 mg twice daily 7-14 days
Bone/joint infections 500-750 mg twice daily 4-6 weeks
Infectious diarrhea 500 mg twice daily 5-7 days
Typhoid fever 500 mg twice daily 10 days
Uncomplicated gonorrhea 500 mg as single dose One time

Adult Intravenous Dosing

Infection Type Dosage Duration
Complicated UTI/Pyelonephritis 400 mg every 12 hours 7-14 days
Severe respiratory infections 400 mg every 8 hours 7-14 days
Skin/soft tissue infections 400 mg every 12 hours 7-14 days
Bone/joint infections 400 mg every 8-12 hours 4-6 weeks
Intra-abdominal infections 400 mg every 12 hours (with metronidazole) 7-14 days

Renal Dose Adjustments

  • Normal renal function (CrCl >90 mL/min): Standard dosing
  • Moderate impairment (CrCl 30-60 mL/min): 400 mg IV every 12 hours or 50% of oral dose
  • Severe impairment (CrCl <30 mL/min): 400 mg IV every 24 hours or 50% of oral dose 2

Special Populations

Pediatric Dosing

  • Generally not first-line therapy in children due to potential joint/cartilage toxicity
  • When necessary: 10-20 mg/kg PO every 12 hours (max 750 mg/dose) or 10 mg/kg IV every 8-12 hours (max 400 mg/dose) 3

Elderly

  • No specific dose adjustment needed based on age alone
  • Adjust based on renal function and comorbidities

Specific Infection Protocols

Urinary Tract Infections

  • Uncomplicated cystitis: 250 mg PO twice daily for 3 days
  • Complicated UTI/Pyelonephritis: 500 mg PO twice daily for 7-14 days or 400 mg IV every 12 hours 3

Gonorrhea

  • 500 mg PO as a single dose (though no longer recommended as first-line due to resistance) 3

Endocarditis (HACEK organisms)

  • 500 mg PO twice daily or 400 mg IV twice daily for 4 weeks 3

Skin and Soft Tissue Infections

  • 400 mg IV every 12 hours (often combined with metronidazole for polymicrobial infections) 3

Important Considerations and Precautions

  1. Resistance patterns: Local resistance patterns should guide empiric therapy choices. Fluoroquinolone resistance is increasing in many regions.

  2. Drug interactions: Avoid concurrent administration with:

    • Magnesium/aluminum antacids
    • Sucralfate
    • Products containing calcium, iron, or zinc
    • Tizanidine (contraindicated)
  3. Timing with other medications: Take ciprofloxacin 2 hours before or 6 hours after interacting products.

  4. Adverse effects to monitor:

    • Tendinopathy/tendon rupture (higher risk in elderly, those on corticosteroids)
    • CNS effects (dizziness, confusion, headache)
    • QT prolongation
    • Photosensitivity
    • C. difficile-associated diarrhea
  5. Hydration: Patients should drink fluids liberally to prevent crystalluria.

  6. Renal function: Dose adjustment required for CrCl <60 mL/min.

Common Pitfalls to Avoid

  1. Overuse in uncomplicated infections: Reserve for appropriate indications to minimize resistance development.

  2. Inadequate dosing for severe infections: Higher doses (750 mg PO or 400 mg IV q8h) are needed for severe infections.

  3. Failure to adjust for renal function: Can lead to toxicity in patients with impaired renal function.

  4. Inappropriate use in children: Not first-line therapy in pediatric patients due to risk of arthropathy.

  5. Missing drug interactions: Especially with antacids, minerals, and dairy products, which can significantly reduce absorption.

  6. Inadequate duration: Too short a course may lead to treatment failure and resistance development.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.